Nektar: REZOLVE-AA 52-wk SALT≤20 at 25.8% (low) and 27.6% (high) vs 6.7% placebo; p=0.049

NEKTAR THERAPEUTICS

SALT≤20 responders nearly doubled from week 36: low dose 25.8% (from 14.8%), high dose 27.6% (from 15.6%), placebo unchanged at 6.7%.
SALT≤30 at wk52: 30.2% low, 35.0% high vs 8.4% placebo (p=0.023). SALT50: 37.7% low, 38.8% high vs 13.6% placebo.
94% of 31 patients completed 16-week extension; no discontinuations due to TEAEs. Injection site reactions mild-to-moderate, self-resolving within 5 days.
Nektar will submit results to a medical conference in 2026 and plans to advance rezpegaldesleukin into registrational trials in alopecia areata.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.